Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy*
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND Human gammadelta T cells can be activated by phospho-antigens and aminobisphosphonates such as zoledronate. Because they can kill tumor cells in a major histocompatibility complex (MHC)-unrestricted manner, adoptive transfer of activated gammadelta T cells may represent a novel cancer immunotherapy. We tested whether gammadelta T cells from advanced cancer patients can be expanded by zoledronate. METHODS Peripheral blood mononuclear cells from healthy donors and patients with advanced non-small cell lung cancer, bone metastatic breast or prostate cancer, or lung metastatic colorectal cancer, were stimulated with zoledronate (5 microM) and interleukin (IL)-2 (1000 IU/mL) for 14 days. The phenotype and function of the expanded gammadelta T-cell populations from healthy donors and cancer patients were compared. RESULTS Gammadelta T cells from cancer patients and healthy donors responded to zoledronate equally well in terms of both phenotype and function. gammadelta T cells grew rapidly in vitro and expression of effector molecules, such as interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, perforin, granzyme B, FasL and TRAIL, increased over time. Cytotoxicity peaked on days 12-14, and proliferation continued up to 14 days, during which time>1x10(9) gammadelta T cells could be obtained from a starting sample of 45-70 mL peripheral blood. DISCUSSION Using the agent zoledronate, already widely used in the clinic, we have established that efficient large-scale ex vivo expansion of gammadelta T cells from cancer patients is possible. These cells exert potent cytotoxicity and may be used for autologous cellular immunotherapy of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
γδ T cells: functional plasticity and heterogeneity
Carding, S. R., & Egan, P. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri797 · Cited by 814
Cited by
Innate Immune Recognition of Cancer
Woo, S.-R., Corrales, L., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 571
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
Jena, B., Dotti, G., & Cooper, L. J. N. (2010) · Blood · doi:10.1182/blood-2010-01-043737 · Cited by 297
Xu, Y., Xiang, Z., Alnaggar, M., Kouakanou, L., Li, J., He, J., Yang, J., Hu, Y., Chen, Y., Lin, L., et al. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0515-7 · Cited by 263
Figueroa, J. A., Reidy, A., Mirandola, L., Trotter, K., Suvorava, N., Figueroa, A., Konala, V., Aulakh, A., Littlefield, L., Grizzi, F., et al. (2015) · International Reviews of Immunology · doi:10.3109/08830185.2015.1018419 · Cited by 78
Kast, R. E. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030153 · Cited by 5
Metadata
- Authors
- Kondo, M., Sakuta, K., Noguchi, A., Ariyoshi, N., Sato, K., Sato, S., Sato, K., Hosoi, A., Nakajima, J., Yoshida, Y., Shiraishi, K., Nakagawa, K., & Kakimi, K.
- Venue
- Cytotherapy
- Publisher
- Elsevier BV
- Published
- 2008
- Volume
- 10
- Issue
- 8
- Pages
- 842-856
- ISSN
- 1465-3249 (ISSN-L)
- OpenAlex
- W1988862024
- Cited by
- 163
- References
- 1
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy*. https://app.cochat.ai/papers/10.1080/14653240802419328
- The paper
- Kondo, M., Sakuta, K., Noguchi, A., Ariyoshi, N., Sato, K., Sato, S., Sato, K., Hosoi, A., Nakajima, J., Yoshida, Y., Shiraishi, K., Nakagawa, K., & Kakimi, K. (2008). Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy*. Cytotherapy. https://doi.org/10.1080/14653240802419328
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.